跳轉至內容
Merck
全部照片(1)

重要文件

檢視所有文件

M-136

Supelco

甲氨蝶呤，1 X 100MG 溶液

1.0 mg/mL in methanol with 0.1N NaOH, ampule of 1 mL, certified reference material, Cerilliant®

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C20H22N8O5
CAS號碼:
59-05-2
分子量：:
454.44
MDL號碼:
MFCD00064369
分類程式碼代碼:
41116107
PubChem物質ID:
329817872
NACRES:
NA.24

等級

certified reference material

形狀

liquid

特點

Snap-N-Spike®/Snap-N-Shoot®

包裝

ampule of 1 mL

製造商／商標名

Cerilliant®

濃度

1.0 mg/mL in methanol with 0.1N NaOH

技術

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

應用

pharmaceutical (small molecule)

形式

single component solution

儲存溫度

−20°C

SMILES 字串

O=C(C1=CC=C(N(C)CC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1)NC(C(O)=O)CCC(O)=O

InChI

1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)

InChI 密鑰

FBOZXECLQNJBKD-UHFFFAOYSA-N

相關類別

一般說明

经认证的加标溶®液，用于通过HPLC或LC/MS进行治疗药物监测（TDM）分析。甲氨蝶呤用于癌症和自身免疫性疾病的治疗，是一种抗代谢和抗叶酸药物，由临床实验室监测，以确保患者保持在药物治疗范围内。Snap-N-Spike®格式允许实验室消除甲氨蝶呤等有害物质的称重操作，显著减少与处理急性毒性粉末有关的职业暴露危害，并提供在使用前将其加标到其选择的基质中的能力。

法律資訊

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

訊號詞

Danger

危險分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - Met. Corr. 1 - STOT SE 1

標靶器官

Eyes,Central nervous system

儲存類別代碼

3 - Flammable liquids

水污染物質分類（WGK）

WGK 2

閃點（°F）

51.8 °F - closed cup

閃點（°C）

11 °C - closed cup

從最近期的版本中選擇一個：

分析證明 (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如果您需要協助，請聯絡 客戶支援

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Joshua F Baker et al.
Annals of the rheumatic diseases, 73(11), 1968-1974 (2013-08-02)
To determine if early MRI measures predict X-ray progression at 1 and 2 years in a large RA trial cohort. This study included 256 methotrexate (MTX)-naïve RA patients from a randomised placebo-controlled trial of golimumab (GO-BEFORE). MRIs of wrist and 2nd-5th
Josef S Smolen et al.
Lancet (London, England), 383(9914), 321-332 (2013-10-31)
Biological agents offer good control of rheumatoid arthritis, but the long-term benefits of achieving low disease activity with a biological agent plus methotrexate or methotrexate alone are unclear. The OPTIMA trial assessed different treatment adjustment strategies in patients with early
Daniel H Solomon et al.
The American journal of medicine, 126(8), 730-730 (2013-07-28)
Elevated tumor necrosis factor (TNF)-α likely contributes to the excess cardiovascular risk observed in rheumatoid arthritis. We compared the cardiovascular risk in rheumatoid arthritis patients starting a TNF-α blocking agent versus a nonbiologic disease-modifying antirheumatic drug (nbDMARD). Subjects with rheumatoid
James R O'Dell et al.
The New England journal of medicine, 369(4), 307-318 (2013-06-13)
Few blinded trials have compared conventional therapy consisting of a combination of disease-modifying antirheumatic drugs with biologic agents in patients with rheumatoid arthritis who have active disease despite treatment with methotrexate--a common scenario in the management of rheumatoid arthritis. We
Richard Conway et al.
Arthritis & rheumatology (Hoboken, N.J.), 66(4), 803-812 (2014-04-24)
Methotrexate has shown efficacy for the treatment of several diseases, especially rheumatoid arthritis (RA). Methotrexate has also been implicated as a causative agent in interstitial lung disease. Patients with RA may develop pulmonary manifestations of their disease and are at
查看所有相關論文

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務